Weekly Recap: Overcharging dues and 12% quarterly sales growth

Cipla Ltd (NSE:CIPLA) reported quarterly sales growth of 12%, estimated at approximately 6–8% excluding the contribution from acquisitions. It had ₹3,576.54 crore in drug price overcharging dues as of March 2026, including interest and recovered sums, with most cases under litigation or awaiting further action.

Previous Week Recap

• ₹3,576.54 Crore Dues Face Litigation: Cipla (CIPLA) had ₹3,576.54 crore in drug price overcharging dues as of March 2026, including interest and recovered sums. Most cases are under litigation or await further action.
  • 
  Business Line
• Sales Growth 12%, Organic 6–8%: Cipla Ltd (CIPLA) reported quarterly sales growth of 12%. Excluding the contribution from acquisitions, growth was estimated at approximately 6–8%.
  • 
  Economic Times
• Nirmal Bang Names Cipla Buy: Nirmal Bang named Cipla (CIPLA) a buy in its 2026 Diwali stock picks, setting a target price of ₹1,801 versus a listed price of ₹1,397.
  • 
  Moneycontrol